Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 11/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15076241 | 0.91 | PLA2G4A (0.41) | PTGER1CYP1A2 | |
| SCHEMBL15076243 | 0.91 | ALDH1A1 (0.40) | TSHRPTGER1CYP1A2MAOAMAOB | |
| SCHEMBL15058170 | 0.89 | NLRP3 (0.44) | PTGER1MAOAMAOB | |
| SCHEMBL15058139 | 0.87 | PTGER1 (0.36) | MEN1KMT2APTGER1CYP1A2TP53 | |
| SCHEMBL15057809 | 0.86 | KDM4E (0.43) | KDM4EMEN1KMT2APTGER1TP53 | |
| SCHEMBL15057605 | 0.84 | PTGER1 (0.40) | PTGER1CYP1A2MAOAMAOBHDAC2 | |
| SCHEMBL15057991 | 0.84 | KDM4E (0.39) | KDM4EMEN1GAATSHRKMT2A | |
| SCHEMBL15057337 | 0.84 | PTGER1 (0.55) | PTGER1CYP1A2 | |
| SCHEMBL15057147 | 0.84 | MAPT (0.38) | KDM4EMEN1TSHRKMT2APTGER1 | |
| SCHEMBL15076183 | 0.83 | PTGER1 (0.35) | KDM4EMEN1GAATSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210221810-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. | 2021-07-22 | — | — | US | disclosed |
| US-10988474-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3424904-B1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200216440-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2020-07-09 | — | — | US | disclosed |
| US-10392382-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20170137423-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170137423-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2017-05-18 | — | — | US | disclosed |
| US-9567328-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567328-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20130184463-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184463-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013096496-A2 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216440-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER2 | KDM4E 1682/4885MEN1 4767/4885GAA 4727/4885 |
| US-20210221810-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER2 | KDM4E 1682/4885MEN1 4767/4885GAA 4727/4885 |
| US-10392382-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | PTGER1, PTGER4, PTGER2 | KDM4E 1682/4885MEN1 4767/4885GAA 4727/4885 |
| US-10988474-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | PTGER1, PTGER4, PTGER2 | KDM4E 1682/4885MEN1 4767/4885GAA 4727/4885 |
| US-20130184463-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER2 | KDM4E 1682/4885MEN1 4767/4885GAA 4727/4885 |
| US-20170137423-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER2 | KDM4E 1682/4885MEN1 4767/4885GAA 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.